Movement Disorders

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 26, 2022.

Branaplam, an mRNA splicing modifier, was being evaluated in a cohort of 75 participants with early manifest Huntington disease, using change in mutant huntingtin protein as the primary outcome measure.

The Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic discussed the complexities with identifying viable biomarkers for Parkinson disease, as well as interventions geared toward specific regions of the brain. [WATCH TIME: 4 minutes]

The Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic discussed a new virtual reality tool that quantifies prodromal changes in activities of daily living for Parkinson disease, without incurring issues of sensory fatigue.

The Edward F. and Barbara A. Bell Endowed Chair at the Cleveland Clinic detailed how a new virtual reality tool elucidates prodromal symptoms from patients with Parkinson disease. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 19, 2022.

The Edward F. and Barbara A. Bell Family Endowed Chair at Cleveland Clinic discussed seamless adjustment made by patients with Parkinson disease to virtual reality, and the benefits it may bring to care. [WATCH TIME: 4 minutes]

In the first report evaluating transcutaneous auricular VNS in patients with Parkinson disease, significant changes were observed in stride length, swing amplitude, gait speed, and gait time.

Despite the availability of medications to relieve OFF episodes in Parkinson disease, widespread adoption of on-demand therapies has been less-than-ideal, marking the need to shift the treatment paradigm in PD.

The Edward F. and Barbara A. Bell Family Endowed Chair at the Cleveland Clinic provided an overview of the Cleveland Clinic Virtual Reality Shopping platform, a virtual reality tool for Parkinson disease. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis.

Neurology News Network for the week of August 13, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 12, 2022.

Valine at position 11, the most significantly associated amino acid, was found in 26% of controls and 22% of individuals with Parkinson disease.

Investigators identified increased levels of neurofilament light that corresponded significantly with patients’ diabetic status, even after adjustment for age, BMI, and vascular risk factors.

After Reata Pharmaceuticals submitted an analysis from the MOXIe extension study of the investigational agent as part of the NDA submission, the FDA extended the PDUFA date to February 2023.

In a phase 2 trial, pepinemab significantly improved metabolic activity as detected by FDG-PET in the majority of brain regions examined, as well as correlated with changes in cognition across both Huntington disease and Alzheimer disease.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromyelitis optica spectrum disorder.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 5, 2022.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.